Dostarlimab Plus Chemo Wins MHRA Approval for dMMR/MSI-H Primary Advanced/Recurrent

October 6, 2023Ashling WahnerThe Medicines and Healthcare Products Regulatory Agency has authorized the use of dostarlimab in combination with chemotherapy for the treatment of patients with mismatch

Updated on: October 09,2023 80

Dostarlimab Plus Chemo Wins MHRA Approval for dMMR/MSI-H Primary Advanced/Recurrent

October 6, 2023Ashling WahnerThe Medicines and Healthcare Products Regulatory Agency has authorized the use of dostarlimab in combination with chemotherapy for the treatment of patients with mismatch

Updated on:October 09,2023 80

European Approval Sought for Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC

October 6, 2023Kristi RosaA Type II extension of indication application seeking the approval of amivantamab in combination with carboplatin and pemetrexed for the frontline treatment of adult patients

Updated on: October 09,2023 181

European Approval Sought for Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC

October 6, 2023Kristi RosaA Type II extension of indication application seeking the approval of amivantamab in combination with carboplatin and pemetrexed for the frontline treatment of adult patients

Updated on:October 09,2023 181

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

September 26, 2023Pankit Vachhani, MD Prithviraj Bose, MDThe hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal t

Updated on: October 10,2023 296

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

September 26, 2023Pankit Vachhani, MD Prithviraj Bose, MDThe hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal t

Updated on:October 10,2023 296

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

September 20, 2023Ashling WahnerEarly lung-specific response to atezolizumab plus bevacizumab was associated with longer overall survival in patients with hepatocellular carcinoma with pulmonary metas

Updated on: October 10,2023 163

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

September 20, 2023Ashling WahnerEarly lung-specific response to atezolizumab plus bevacizumab was associated with longer overall survival in patients with hepatocellular carcinoma with pulmonary metas

Updated on:October 10,2023 163

IMNN-001 Plus Neoadjuvant Chemotherapy Improves PFS in Advanced Ovarian Cancer

September 28, 2023Chris RyanTreatment with the interleukin-12 gene-mediated immunotherapy IMNN-001 in combination with neoadjuvant platinum chemotherapy led to an improvement in progression-free survi

Updated on: October 10,2023 280

IMNN-001 Plus Neoadjuvant Chemotherapy Improves PFS in Advanced Ovarian Cancer

September 28, 2023Chris RyanTreatment with the interleukin-12 gene-mediated immunotherapy IMNN-001 in combination with neoadjuvant platinum chemotherapy led to an improvement in progression-free survi

Updated on:October 10,2023 280

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

September 30, 2023Courtney FlahertyPatients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class

Updated on: October 10,2023 265

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

September 30, 2023Courtney FlahertyPatients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class

Updated on:October 10,2023 265

Helping blood cells regenerate after radiation therapy

Method boosts differentiation of stem cells into mature blood cell types, may help leukemia and lymphoma patients.Anne Trafton|MIT News OfficePublication Date:October 24, 2018 PRESS INQUIR

Updated on: October 11,2023 239

Helping blood cells regenerate after radiation therapy

Method boosts differentiation of stem cells into mature blood cell types, may help leukemia and lymphoma patients.Anne Trafton|MIT News OfficePublication Date:October 24, 2018 PRESS INQUIR

Updated on:October 11,2023 239

Biologists identify key step in lung cancer evolution

Blocking the transition to a more aggressive state could offer a new treatment strategy.Anne Trafton|MIT News OfficePublication Date:May 10, 2017 PRESS INQUIRIESCaption:MIT researche

Updated on: October 11,2023 66

Biologists identify key step in lung cancer evolution

Blocking the transition to a more aggressive state could offer a new treatment strategy.Anne Trafton|MIT News OfficePublication Date:May 10, 2017 PRESS INQUIRIESCaption:MIT researche

Updated on:October 11,2023 66

Exploring the links between diet and cancer

Omer Yilmaz’s work on how diet influences intestinal stem cells could lead to new ways to treat or prevent gastrointestinal cancers.Anne Trafton|MIT News OfficePublication Date:May 25, 202

Updated on: October 11,2023 130

Exploring the links between diet and cancer

Omer Yilmaz’s work on how diet influences intestinal stem cells could lead to new ways to treat or prevent gastrointestinal cancers.Anne Trafton|MIT News OfficePublication Date:May 25, 202

Updated on:October 11,2023 130

EMA Grants PRIME Designation to Iopofosine I-131 for Waldenström Macroglobulinemia

September 18, 2023Kristi RosaThe European Medicines Agency has granted Priority Medicines designation to iopofosine I-131 for use in patients with Waldenström macroglobulinemia in patients who previou

Updated on: October 11,2023 148

EMA Grants PRIME Designation to Iopofosine I-131 for Waldenström Macroglobulinemia

September 18, 2023Kristi RosaThe European Medicines Agency has granted Priority Medicines designation to iopofosine I-131 for use in patients with Waldenström macroglobulinemia in patients who previou

Updated on:October 11,2023 148

Luspatercept Provides Frontline Alternative to ESAs For Lower-Risk MDS and Anemia

September 21, 2023Courtney FlahertyUwe Platzbecker, MD, discusses the efficacy and safety data from the COMMANDS trial that supported the approval, and the next steps planned for luspatercept’s invest

Updated on: October 11,2023 261

Luspatercept Provides Frontline Alternative to ESAs For Lower-Risk MDS and Anemia

September 21, 2023Courtney FlahertyUwe Platzbecker, MD, discusses the efficacy and safety data from the COMMANDS trial that supported the approval, and the next steps planned for luspatercept’s invest

Updated on:October 11,2023 261

DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

September 15, 2023Caroline SeymourTissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression

Updated on: October 11,2023 261

DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

September 15, 2023Caroline SeymourTissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression

Updated on:October 11,2023 261